Aeglea Biotherapeutics Inc. (AGLE) Stock Rating Upgraded by Zacks Investment Research
Aeglea Biotherapeutics Inc. (NASDAQ:AGLE) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday. The brokerage currently has a $6.75 target price on the stock. Zacks Investment Research’s price objective suggests a potential upside of 11.57% from the company’s previous close.
According to Zacks, “Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical trial phase. Aeglea BioTherapeutics, Inc. is based in Austin, Texas. “
Separately, BMO Capital Markets restated a “buy” rating and set a $19.00 target price on shares of Aeglea Biotherapeutics in a research report on Thursday, November 10th.
Shares of Aeglea Biotherapeutics (NASDAQ:AGLE) opened at 6.05 on Friday. The stock’s 50 day moving average is $6.35 and its 200-day moving average is $6.16. The stock’s market cap is $81.14 million. Aeglea Biotherapeutics has a 12-month low of $3.89 and a 12-month high of $12.75.
A number of large investors have recently added to or reduced their stakes in AGLE. Ghost Tree Capital LLC purchased a new position in shares of Aeglea Biotherapeutics during the second quarter worth $243,000. Perceptive Advisors LLC purchased a new position in shares of Aeglea Biotherapeutics during the second quarter worth $515,000. VHCP Management II LLC bought a new stake in Aeglea Biotherapeutics during the second quarter worth approximately $1,527,000. Baker BROS. Advisors LP bought a new stake in Aeglea Biotherapeutics during the third quarter worth approximately $2,591,000. Finally, University of Texas Investment Managment Co. bought a new stake in Aeglea Biotherapeutics during the third quarter worth approximately $3,365,000. 44.94% of the stock is owned by institutional investors.
About Aeglea Biotherapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.
Receive News & Stock Ratings for Aeglea Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.